DrugPatentWatch Database Preview
Hikma Intl Pharms Company Profile
» See Plans and Pricing
What is the competitive landscape for HIKMA INTL PHARMS, and when can generic versions of HIKMA INTL PHARMS drugs launch?
HIKMA INTL PHARMS has forty-three approved drugs.
There are five US patents protecting HIKMA INTL PHARMS drugs.
Summary for Hikma Intl Pharms
| US Patents: | 5 |
| Tradenames: | 30 |
| Ingredients: | 30 |
| NDAs: | 43 |
Drugs and US Patents for Hikma Intl Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma Intl Pharms | MITIGARE | colchicine | CAPSULE;ORAL | 204820-001 | Sep 26, 2014 | RX | Yes | Yes | 9,399,036 | Start Trial | Start Trial | ||||
| Hikma Intl Pharms | ONDANSETRON HYDROCHLORIDE | ondansetron hydrochloride | TABLET;ORAL | 077545-001 | Sep 6, 2007 | DISCN | No | No | Start Trial | Start Trial | |||||
| Hikma Intl Pharms | DOPAMINE HYDROCHLORIDE | dopamine hydrochloride | INJECTABLE;INJECTION | 207707-002 | Apr 11, 2018 | AP | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for HIKMA INTL PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 0.6 mg | ➤ Subscribe | 2016-06-10 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
